Purchase this article with an account.
Thais Mendes, Moreno Menghini, Ashleigh Levison, Soraya Rofagha, Robert Bhisitkul; Retinal and choroidal thickness changes over time in patients with neovascular age-related macular degeneration treated with anti-VEGF. Invest. Ophthalmol. Vis. Sci. 2013;54(15):6265.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
to assess changes over time in central macular thickness,central foveal thickness,volume and choroidal thickness in patients with exudative age-related macular degeneration (AMD) treated with intravitreal anti-VEGF using spectral-domain optical coherence tomography (SD-OCT).
Consecutive subjects with exudative AMD were studied. Data from January 2008 to October 2012 was reviewed. Inclusion criteria: minimum of 3 anti-VEGF injections and at least 6-month follow up. SD-OCTs at time-points without signs of CNV activity were analyzed (i.e. no subretinal and/or intraretinal fluid). Patients with evidence of subfoveal fibrosis,epiretinal membrane,macular hole,high myopia and CNV other than AMD were excluded. Measurements were obtained by Spectralis (Heidelberg, Germany) and Image J® software, including Central Foveal Thickness (CFT), Central macular thickness (CMT), macular volume and choroidal thickness. Manual correction was performed on retinal thickness b-scans.Baseline OCT image was compared with last follow-up visit. Changes between baseline and follow-up CFT,CMT,macular volume and choroidal thickness were calculated.
20 eyes of 20 patients with exudative AMD were analyzed. 55% of patients were female with mean age of 86.9 years ±6.53. The mean study interval was 25.9 months (±11.78, range 7.5-4.5). The mean baseline best-corrected visual acuity was 20/95 (0.68 logMAR, ± 0.39) and after injections was 20/67 (0.53 logMAR ± 0.38). Mean number of injections was 11. Mean baseline CFT, CMT, macular volume at 6mm, macular volume at 3mm and choroidal thickness were 224.05 μm ± 37.31, 259.1μm ±29.16, 7.51 mm3 ±0.85, 2.08 mm3 ± 0.14 and 172.3μm ± 80.59, respectively. From baseline to final exam, CFT showed 24.25 μm decrease to a mean of 199.8μm ±32.05 (p=0.001). The CMT showed 4.45μm ± 21.22 decrease to a mean of 254.65μm ±35.54 (p=0.180). Macular volume at 6mm showed 0.15 ±0.22 decrease to a mean of 7.36mm3 ±0.87 (p=0.0041) and at 3mm showed 0.05mm3 ±0.11 decrease to a mean of 2.01 mm3 ±0.16 (p=0.0159). The choroidal thickness showed 11.65μm ± 11.38 decrease to a mean of 160.65μm ±76.43 (p=0.0001). CFT thinining was observed in 90% of patients (p=0.0001).
After a time interval, treated patients with exudative AMD underwent a reduction in central foveal thickness,central macular thickness,macular volume and choroidal thickness.
This PDF is available to Subscribers Only